CardioFocus QuickShot Nav Large-Area Focal PFA Catheter Evaluated in Quick AF Trial

April 21, 2025—CardioFocus, Inc. recently announced the continuation of enrollment in the Quick AF study, which is evaluating the company’s QuickShot Nav large-area, focal, pulsed field ablation (PFA) catheter for the treatment of persistent atrial fibrillation (AF). The device is investigational and not approved for commercial use, advised the company.

The latest patient cases were performed by the study’s Principal Investigator, Ante Anić, MD, at KBC Split in Split, Croatia.

“The QuickShot Nav catheter is a highly versatile tool with a wide range of applications in AF ablation,” commented Dr. Anić in the CardioFocus press release. “Its design allows for flexible manipulation and the ability to map and ablate with a single device. This makes it an exciting addition to the field, as it requires fewer applications compared to traditional methods while maintaining precision and allowing physicians the flexibility to determine lesion locations. I am optimistic about the impact this device will have on clinical practice.”

According to CardioFocus, the QuickShot Nav system is designed to support safe, effective, and efficient AF ablation workflows, including pulmonary vein isolation (PVI) and beyond (PVI+). The company advised that the study protocol gives the physician latitude to do additional lesion lines of ablation beyond a PVI-only approach, including posterior wall isolation, cavotricuspid isthmus line, and mitral isthmus line.

The company stated that the QuickShot Nav device requires fewer applications to achieve flexible lesion sets and includes a magnetic navigation sensor to facilitate compatibility with magnetically enabled electroanatomic mapping systems. Also, the company noted that Quick Shot Nav harnesses the CardioFocus Wave1 PFA waveform, which was launched commercially in the European Union and United Kingdom in August 2022.

In the coming months, the Quick AF trial will include remapping to assess lesion durability and optimized outcomes before continuation into a broader pivotal trial later this year, stated CardioFocus.